Pre-order Enquiry
Request Free Sample
Global Aclidinium Bromide Market Insights, Forecast to 2028
SKU ID : QYR-20154937 | Publishing Date : 08-Feb-2022 | No. of pages : 95
Request Sample
Request Customization
Check Discounts
Aclidinium bromide (INN) is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the US as a maintenance treatment for chronic obstructive pulmonary disease
Market Analysis and Insights: Global Aclidinium Bromide Market
Due to the COVID-19 pandemic, the global Aclidinium Bromide market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 322µg accounting for % of the Aclidinium Bromide global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Aclidinium Bromide market size is valued at US$ million in 2021, while the US and Europe Aclidinium Bromide are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Aclidinium Bromide landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Aclidinium Bromide include Menarini, Almirall, AstraZeneca, Berlin Chemie, Boc Sciences, Circassia Pharmaceuticals, Teva and Yuhao Chemical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Aclidinium Bromide Scope and Segment
Aclidinium Bromide market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Aclidinium Bromide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
322µg
340µg
400µg
Segment by Application
Hospital
Drug Store
By Company
Menarini
Almirall
AstraZeneca
Berlin Chemie
Boc Sciences
Circassia Pharmaceuticals
Teva
Yuhao Chemical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Aclidinium Bromide Market
Due to the COVID-19 pandemic, the global Aclidinium Bromide market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 322µg accounting for % of the Aclidinium Bromide global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Aclidinium Bromide market size is valued at US$ million in 2021, while the US and Europe Aclidinium Bromide are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Aclidinium Bromide landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Aclidinium Bromide include Menarini, Almirall, AstraZeneca, Berlin Chemie, Boc Sciences, Circassia Pharmaceuticals, Teva and Yuhao Chemical, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Aclidinium Bromide Scope and Segment
Aclidinium Bromide market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Aclidinium Bromide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
322µg
340µg
400µg
Segment by Application
Hospital
Drug Store
By Company
Menarini
Almirall
AstraZeneca
Berlin Chemie
Boc Sciences
Circassia Pharmaceuticals
Teva
Yuhao Chemical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
